Capital Advantage, Inc. Amgen Inc Transaction History

Capital Advantage, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$233.58 - $259.14 $692,097 - $767,831	-2,963 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$221.91 - $258.6 $62,578 - $72,925	282 Added 10.52%	2,963 $737,000
Q4 2020 Feb 17, 2021	BUY	$216.38 - $257.67 $30,509 - $36,331	141 Added 5.55%	2,681 $611,000
Q3 2020 Nov 12, 2020	SELL	$234.65 - $260.95 $11,497 - $12,786	-49 Reduced 1.89%	2,540 $655,000
Q2 2020 Aug 13, 2020	BUY	$197.81 - $242.74 $12,264 - $15,049	62 Added 2.45%	2,589 $611,000
Q1 2020 May 08, 2020	BUY	$182.24 - $241.7 $21,504 - $28,520	118 Added 4.9%	2,527 $594,000
Q4 2019 Feb 14, 2020	SELL	$189.21 - $243.2 $26,300 - $33,804	-139 Reduced 5.46%	2,409 $543,000
Q3 2019 Nov 12, 2019	BUY	$174.11 - $208.62 $80,264 - $96,173	461 Added 22.09%	2,548 $493,000
Q1 2019 May 10, 2019	BUY	$180.87 - $203.88 $15,735 - $17,737	87 Added 4.35%	2,087 $396,000
Q4 2018 Feb 07, 2019	BUY	$178.4 - $208.25 $1,427 - $1,666	8 Added 0.4%	2,000 $389,000
Q3 2018 Nov 01, 2018	SELL	$185.29 - $208.89 $10,932 - $12,324	-59 Reduced 2.88%	1,992 $413,000
Q2 2018 Aug 01, 2018	SELL	$166.05 - $186.51 $7,638 - $8,579	-46 Reduced 2.19%	2,051 $379,000
Q1 2018 May 02, 2018	BUY	$169.43 - $198.0 $4,574 - $5,346	27 Added 1.3%	2,097 $357,000
Q4 2017 Feb 13, 2018	SELL	$168.79 - $188.59 $12,996 - $14,521	-77 Reduced 3.59%	2,070 $360,000
Q3 2017 Oct 30, 2017	BUY	$167.29 - $191.0 $1,840 - $2,101	11 Added 0.51%	2,147 $400,000
Q2 2017 Aug 08, 2017	BUY	N/A	2,136	2,136 $368,000

3,122

410M

7.56M

7.2M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $155B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Capital Advantage, Inc., based on Form 13F filings with the SEC.

Stay updated on Capital Advantage, Inc. with notifications on news.